Peer Reviewed Journals

O'Dwyer, M,Atallah, E (2009) 'Practical Considerations for the Management of Patients in the Tyrosine Kinase Inhibitor Era'. Seminars In Hematology, 46 :16-21. [DOI] [Details]

Meenaghan T, O'Dwyer M, Hayden P, Hayat A, Murray M, Dowling M. Home (2010) 'administration of bortezomib: making a difference to myeloma patients' lives. Eur'. J Oncol Nurs, 14 (2):134-136. [Details]

Swords R, Mahalingam D, O'Dwyer M, Santocanale C, Kelly K, Carew J, Giles F. (2010) 'Cdc7 kinase - a new target for drug development'. Eur J Cancer, 46 (1):33-40. [Details]

Krawczyk J, Ansar N, Swords R, Murphy T, MacDonagh B, Meenaghan T, Hayden P,Hayad A, Murray M, O'Dwyer M. (2010) 'Clofarabine in the treatment of poor risk acute myeloid leukaemia'. Hematol Oncol, 28 (3):118-123. [DOI] [Details]

Cronin CG, Swords R, Truong MT, Viswanathan C, Rohren E, Giles FJ, O'Dwyer M, (2010) 'Bruzzi JF. Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol. 2010'. Review, 191 (1):W91-W103. [DOI] [Details]

Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K,Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ, Carew JS (2010) 'Inhibition of EDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia'. Blood, 115 (18):3796-3800. [DOI] [Details]

Van Dijk M, Murphy E, Morrell R, Knapper S, O'Dwyer M, Samali A and Szegezdi E. (2011) 'The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic'. Differentiation to TRAIL Mediated Apoptosis Cancers, 3 (1):1329-1350. [DOI] [Details]

McCarron SL, Kelly J, Coen N, McCabe S, Fay M, O'Dwyer M, Hayden PJ, Langabeer (2011) 'SE. A novel e8a2 BCR-ABL1 fusion with insertion of RALGPS1 exon 8 in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia'. Leuk Lymphoma, 52 (5):919-921. [Details]

     

Abstract

O'Dwyer, MC,Kent, E,Parker, M,Swords, RT,Giles, F,le Coutre, P,Padmanabhan, S,Moulton, B,McMullin, MF,Langabeer, S,Egan, K,Conneally, E (2009) Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study. Abstract [Details]